NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will try to define an appropriate dose of the investigational drug indocyanine green (ICG) in combination with near infrared (NIR) imaging to use for future studies.

ICG is a dye which has been in use since the 50s, and is approved for testing liver function and measuring blood flow from the heart. It has been used in studies to map lymphatic pathways in lung and breast cancer and information from those studies suggest it may help identify lymph nodes associated with melanoma. ICG can be detected within the body using near-infrared light cameras.

In this study the investigators are looking at how easily ICG can get to the first lymph node (sentinel lymph node \[SLN\]) associated with melanoma, whether the investigators can see the path of the ICG and the SLN using a near infrared camera, and what dose of ICG works the best. While the current method for SNL mapping, known as lymphoscintigraphy, is effective it does provide a small amount of radiation. This study will compare the investigators results to the standard procedure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Second Echelon Node Study With Methylene Blue

NCT01823172

Breast Cancer Melanoma

COMPLETED NA

Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients

NCT02479997

Breast Cancer

COMPLETED PHASE2

Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer

NCT07146295

Breast Cancer Sentinel Lymph Node Biopsy (SLNB) Sentinel Lymph Node Detection +6 more

RECRUITING NA

ICG and SLN Mapping

NCT05859971

Breast Cancer

COMPLETED EARLY_PHASE1

Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research

NCT02084784

Sentinel Lymph Node Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At the time of surgery, you will undergo a lymphoscintigraphic procedure which is standard of care for patients with melanoma. You will also receive a dose of ICG mixed with human serum albumin. This will be administered in four small injections immediately around your tumor or the tumor scar if it has already been removed. Pictures of the ICG solution will be taken with the NIR camera and the progression of the dye along the lymphatic channel from your tumor to the SLN will be monitored.

As each lymph node is removed, pictures will be taken to see if the ICG dye has entered and colored that node. We will compare this technique with the results from the lymphoscintigraphy to measure accuracy.

Patients will be followed for at least one hour post injection for adverse events. The patient will then be taken off of the study. The results from each intervention will subsequently analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is an experimental study. All study subjects will receive the same intervention.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

This study does not involve any masking.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICG Intervention

Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)

Group Type EXPERIMENTAL

ICG Intervention

Intervention Type DRUG

NIR-guided sentinel lymph node mapping with indocyanine green (ICG)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICG Intervention

NIR-guided sentinel lymph node mapping with indocyanine green (ICG)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NIR fluorescence imaging Sentinel Lymph Node

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed melanoma and an appropriate surgical candidate for a sentinel lymph node biopsy
* Stage of disease conducive to sentinel lymph node biopsy as determined by oncologic surgeon
* Receiving a planned lymphoscintigraphy procedure

Exclusion Criteria

* History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
* Pregnant or breast-feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No